<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">21795409</PMID>
<DateCompleted>
<Year>2012</Year>
<Month>01</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1078-0432</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>17</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2011</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
<ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Interleukin-6 as a therapeutic target in human ovarian cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>6083-96</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-11-0945</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We investigated whether inhibition of interleukin 6 (IL-6) has therapeutic activity in ovarian cancer via abrogation of a tumor-promoting cytokine network.</AbstractText>
<AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">We combined preclinical and in silico experiments with a phase 2 clinical trial of the anti-IL-6 antibody siltuximab in patients with platinum-resistant ovarian cancer.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Automated immunohistochemistry on tissue microarrays from 221 ovarian cancer cases showed that intensity of IL-6 staining in malignant cells significantly associated with poor prognosis. Treatment of ovarian cancer cells with siltuximab reduced constitutive cytokine and chemokine production and also inhibited IL-6 signaling, tumor growth, the tumor-associated macrophage infiltrate and angiogenesis in IL-6-producing intraperitoneal ovarian cancer xenografts. In the clinical trial, the primary endpoint was response rate as assessed by combined RECIST and CA125 criteria. One patient of eighteen evaluable had a partial response, while seven others had periods of disease stabilization. In patients treated for 6 months, there was a significant decline in plasma levels of IL-6-regulated CCL2, CXCL12, and VEGF. Gene expression levels of factors that were reduced by siltuximab treatment in the patients significantly correlated with high IL-6 pathway gene expression and macrophage markers in microarray analyses of ovarian cancer biopsies.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IL-6 stimulates inflammatory cytokine production, tumor angiogenesis, and the tumor macrophage infiltrate in ovarian cancer and these actions can be inhibited by a neutralizing anti-IL-6 antibody in preclinical and clinical studies.</AbstractText>
<CopyrightInformation>©2011 AACR.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Coward</LastName>
<ForeName>Jermaine</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Barts Cancer Institute, Queen Mary University of London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kulbe</LastName>
<ForeName>Hagen</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chakravarty</LastName>
<ForeName>Probir</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Leader</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vassileva</LastName>
<ForeName>Vessela</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Leinster</LastName>
<ForeName>D Andrew</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Thompson</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schioppa</LastName>
<ForeName>Tiziana</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nemeth</LastName>
<ForeName>Jeffery</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vermeulen</LastName>
<ForeName>Jessica</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Naveena</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Avril</LastName>
<ForeName>Norbert</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cummings</LastName>
<ForeName>Jeff</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rexhepaj</LastName>
<ForeName>Elton</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jirström</LastName>
<ForeName>Karin</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gallagher</LastName>
<ForeName>William M</ForeName>
<Initials>WM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brennan</LastName>
<ForeName>Donal J</ForeName>
<Initials>DJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McNeish</LastName>
<ForeName>Iain A</ForeName>
<Initials>IA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Balkwill</LastName>
<ForeName>Frances R</ForeName>
<Initials>FR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>G0501974</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>A5213</GrantID>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>G0601891</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>G0501974(77044)</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>G0601891(82080)</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>A10603</GrantID>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2011</Year>
<Month>07</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Clin Cancer Res</MedlineTA>
<NlmUniqueID>9502500</NlmUniqueID>
<ISSNLinking>1078-0432</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>T4H8FMA7IM</RegistryNumber>
<NameOfSubstance UI="C504234">siltuximab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Clin Cancer Res. 2011 Dec 15;17(24):7837; author reply 7838</RefSource>
<PMID Version="1">22147939</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biomarkers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019295">Computational Biology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010051">Ovarian Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019947">Receptors, Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">UKMS36081</OtherID>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>7</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>7</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2012</Year>
<Month>1</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">21795409</ArticleId>
<ArticleId IdType="pii">1078-0432.CCR-11-0945</ArticleId>
<ArticleId IdType="doi">10.1158/1078-0432.CCR-11-0945</ArticleId>
<ArticleId IdType="pmc">PMC3182554</ArticleId>
<ArticleId IdType="mid">UKMS36081</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>In Vitro Cell Dev Biol Anim. 2000 Jun;36(6):357-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10949993</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2011 Jan 15;71(2):424-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21123455</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2001 Jul 15;19(14):3312-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11454878</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Invest New Drugs. 2002 Aug;20(3):253-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12201488</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Apoptosis. 2003 Jun;8(3):263-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12766486</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 1994 Apr 1;73(7):1882-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8137215</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 1995 Feb;71(2):354-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7841052</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Med. 1998 Jul;4(7):844-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9662379</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2005 Feb 14;92(3):532-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15685240</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2005 Oct 15;106(8):2627-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15998837</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2005 Oct 20;23(30):7445-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16157939</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2005 Dec 1;65(23):10794-800</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16322225</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2006 Sep 1;12(17):5055-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16951221</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2006 Dec 1;66(23):11432-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17145890</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2007 Jan 15;67(2):585-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17234767</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2007 Jul 1;25(19):2811-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17602086</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2007 Jul 6;317(5834):121-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17615358</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genes Dev. 2007 Jul 15;21(14):1714-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17639077</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2007 Oct 10;25(29):4542-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17925549</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2008 Jan;13(1):7-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18167335</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Mol Med. 2008 Mar;14(3):109-19</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18261959</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2008 May;19(5):990-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18304966</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2011 Apr 15;17(8):2538-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21343371</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bioinformatics. 2004 Feb 12;20(3):307-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14960456</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2004 Jun 1;10(11):3919-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15173101</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2008 Aug 15;14(16):5198-208</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18698038</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15505-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18832156</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2008 Oct 10;26(29):4820-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18779606</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2008 Nov 15;112(10):3959-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18784373</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2009 Feb 1;69(3):1009-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19155309</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2009 Feb 3;15(2):79-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19185839</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2009 Feb 3;15(2):91-102</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19185844</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2009 Feb 3;15(2):103-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19185845</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3806-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19234121</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2009 May;45(8):1510-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19272768</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2010 Mar 1;16(5):1652-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20179212</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Cancer. 2010;10:125</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20359358</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Cancer Drug Targets. 2010 May;10(3):268-78</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20370691</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2010 May 25;102(11):1555-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20502460</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2010 Jun 1;16(11):3028-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20484019</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2010 Aug 10;28(23):3701-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20625121</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Transl Med. 2010;8:78</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20727170</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2010 Dec 1;16(23):5759-69</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20699329</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>